Humanigen Product Lenzilumab Combination with CAR-T

• At the recommended Phase 2 dose, lenzilumab in combination with CAR-T demonstrated a 100% objective response rate and no severe cytokine release syndrome or severe neurotoxicity
• Lenzilumab reduced IL-6, CRP, ferritin, MCP-1, IL-8, and IP-10 (CXCL-10) among others
• Humanigen now plans to conduct a randomized, potentially registrational, Phase 2 study with lenzilumab combined with all commercially available CD19 CAR-T therapies in DLBCL
• Humanigen has terminated the ZUMA-19 clinical collaboration agreement with Kite . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Impacting News

  Gilead Sciences (GILD), Humanigen Inc (HGEN), Kite Pharma - A Gilead Company, SARS-CoV-2 (the virus that causes COVID-19)

  April 21, 2021
  Tweet Pin It